“Coronaneb has the potential to change the future of medicine, others can only dream of “
Nick Havecroft – CEO & Founder Coronaneb
Medication has seen a paradigm shift to inhaled therapy, for both systemic and local drug delivery, due to the lung’s favourable properties of a large surface area and high permeability.
There are over 300 million alveoli in the lung, and each alveolus is lined with pulmonary capillaries forming a huge network comprising over 280 billion capillaries.
The lungs provide a huge surface area of about 70 m2 available as a blood gas barrier. where the distance between the capillaries and alveolar is very small, facilitating drug absorption via diffusion.
Pulmonary drug delivery possesses many advantages, including non-invasive route of administration, low metabolic activity, control environment for systemic absorption and avoids first bypass metabolism.
Particulate-based pulmonary drug delivery systems have emerged as an innovative and promising alternative to conventional drugs to clearance mechanisms and provide enhanced therapeutic efficiency.
Few devices have the ability to deliver drugs with a small enough molecule size allowing the lungs to efficiently absorb the medication.
Nano medication, Biologics, Biosimilars most efficient and cost effective administration is via the pulmonary tract , but there are currently very few, if any devices able to break down the molecules to a size small enough to be efficiently delivered to the pulmonary tract.
Coronaneb has developed a device capable of delivering many forms of medication through the pulmonary tract with a molecule size small enough for efficient absorption into the blood stream.
Provides precise drug delivery to the lung without breath coordination in the (micro fine) nebulized form, suitable for all patient status.
Drug stability is not affected by the ultrasonic vibrating Micron Micro Mesh.
Mesh is made of platinum alloy which is non toxic, durable and resistant to corrosion. 8000 holes per 15mm diameter mesh.
Small Volume, no noise, no heating required, no drug decomposition, effective, reliable and durable. No drug waste with visual assurance of drug delivery.
510 K certification, RoHs and REACH approval.
One of only two FDA approved micro mesh production facilities in the Far East.
Allows tenfold reduction in active ingredient which saves on cost and increases safety.
90% bio availability versus 26% for other inhaler devices.
10 second uptake of medication from the lungs to the brain.
Easy to use, elegant, portable, affordable, easy dose loading reusable, light weight, low residue, no waste, unit dose and multi dose refills.
Want more from Coronaneb? Get notified of new devices, case studies, investor information, latest news and much more. What are you waiting for? Get started and Join the Coronaneb newsletter today..